Trial of CTX 1301 (Dexmethylphenidate) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD)

Trial Profile

Trial of CTX 1301 (Dexmethylphenidate) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Jan 2018

At a glance

  • Drugs Dexmethylphenidate (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus First in man; Pharmacokinetics; Proof of concept
  • Most Recent Events

    • 16 Jan 2018 According to a Cingulate Therapeutics media release, results from this trial were presented at the 2018 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting.
    • 15 Jan 2018 Results presented in a Cingulate Therapeutics media release.
    • 10 Jul 2017 Status changed from recruiting to completed, according to a Cingulate Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top